Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
BVX-20
- Development stage
- Preclinical
- Lead developer
- Biocon
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
BVX-20 is a second-generation, humanized monoclonal antibody targeting the B-cell surface antigen CD20, jointly developed by Biocon and Vaccinex for oncology and potentially neuro-inflammatory indications.[7][11][13] Designed to mediate CD20-directed cytolytic effects such as antibody-dependent cellular cytotoxicity (ADCC), BVX-20 aims to deplete malignant or pathogenic B cells and is positioned as a novel biologic for blood cancers and other CD20-driven diseases; it has reached IND-ready status and entered early clinical development.[3][7][9][11]
- Other names
- BVX20-CD20 antibodyBVX-20-CD20 antibodyBVX 20-CD20 antibody
02
Targets
Beyond the preview
Go deeper on BVX-20.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on BVX-20.